Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series

The frequency of using rituximab to treat refractory nephrotic syndrome has recently been increasing, and the conventional dose of rituximab used to treat it, 375 mg/m(2) body surface area once weekly for 4 weeks, has been modelled on the chemotherapy regimen for B-cell non-Hodgkin's lymphoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Usui, Ryosuke, Tsuchiya, Yohei, Nitta, Kosaku, Koike, Minako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244099/
https://www.ncbi.nlm.nih.gov/pubmed/30479998
http://dx.doi.org/10.1159/000493189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244099/
https://www.ncbi.nlm.nih.gov/pubmed/30479998
http://dx.doi.org/10.1159/000493189

Ejemplares similares